Global PCR Based Transplant Diagnostics Market, By Test Type (CMV PCR Test, EBV PCR Test, BKV PCR Test, VZV PCR Test, HSV1 PCR Test, HSV2 PCR Test, Parvovirus B19 PCR Test, P. Jirovecii PCR Test, JCV PCR Test, Adenovirus PCR Test, and Aspergillus Spp PCR Test), Transplant Type (Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Pancreas Transplantation, and Other Transplantations), Application (Diagnostic Applications and Research Applications), End User (Hospitals and Transplant Centers, Commercial Service Providers, Research Laboratories, and Academic Institutes) - Industry Trends and Forecast to 2031.
PCR Based Transplant Diagnostics Market Analysis and Insights
One of the primary factors driving the growth of the market is the rising prevalence of organ failure. In addition, the rising popularity of non-invasive diagnostic methods across the globe is another key driver for market growth. Advancements in organ preservative techniques also influence the market. However, the shortage of professionals with expertise in transplant diagnostics is restraining the market growth.
On the other hand, strategic initiation and technology launches by the market players act as an opportunity for market growth. However, ethical challenges faced during organ transplantation may create a challenge to market growth.
Data Bridge Market Research analyses that the market is expected to reach USD 995,007.52 thousand by 2031, from USD 612,500.00 thousand in 2023, growing with a CAGR of 6.5% in the forecast period of 2024 to 2031.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Test Type (CMV PCR Test, EBV PCR Test, BKV PCR Test, VZV PCR Test, HSV1 PCR Test, HSV2 PCR Test, Parvovirus B19 PCR Test, P. Jirovecii PCR Test, JCV PCR Test, Adenovirus PCR Test, and Aspergillus Spp PCR Test), Transplant Type (Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Pancreas Transplantation, and Other Transplantations), Application (Diagnostic Applications and Research Applications), End User (Hospitals and Transplant Centers, Commercial Service Providers, Research Laboratories, and Academic Institutes)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Eurofins Viracor, LLC, Sonic Healthcare USA, Ambar Lab, ARUP Laboratories, and Dr. Lal PathLabs among others
|
Market Definition
PCR is a molecular biology technique used to amplify specific DNA sequences, enabling the detection and analysis of genetic material with high precision and sensitivity. In the context of transplant diagnostics, PCR-based assays are employed to assess compatibility between organ donors and recipients, monitor post-transplant outcomes, and detect signs of rejection or complications. The market can be defined as the segment of the healthcare industry that focuses on utilizing PCR technology for diagnostic purposes in organ transplantation procedures.
Global PCR Based Transplant Diagnostics Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increasing Prevalence of Organ Failure
There is a growing demand for organ transplants to save lives and improve the quality of life for affected individuals, as the incidence of organ failure continues to rise. Organs such as kidney, liver, heart, and lungs may fail due to various reasons, including chronic diseases, genetic disorders, or trauma. The growing prevalence of chronic diseases, such as chronic kidney disease, liver disease, and heart disease, contributes to an expanding patient pool in need of organ transplants. These patients often require transplant diagnostics to ensure compatibility between the donor organ and the recipient, minimizing the risk of rejection. Hence, the increasing prevalence of organ failure is driving the market growth.
- Rising Popularity of Non-Invasive Diagnostic Methods
Non-invasive diagnostic methods, such as blood tests and imaging techniques, eliminate the need for invasive procedures such as tissue biopsies. This results in increased patient comfort, leading to higher acceptance and compliance with diagnostic assessments. In the context of transplant diagnostics, non-invasive methods offer a less intrusive way to assess compatibility between donors and recipients. Invasive diagnostic procedures, such as tissue biopsies, carry inherent risks of complications, including bleeding and infection. Non-invasive methods, being less risky, appeal to both patients and healthcare providers. The reduction in the risk of complications is particularly significant in the context of transplant patients who may already be immuno-compromised. Hence, the rising popularity of non-invasive diagnostic methods is driving the market growth.
Opportunity
- Strategic Initiation and Technology Launches by Market Players
The escalating growth in the PCR based transplant diagnostics market, driven by the increased demand for donor organs, emphasizes the strategic initiatives such as partnerships, business expansions, and developmental endeavors. These initiatives, guided by well-thought-out strategies, include the introduction of transplant diagnostic kits, such as the Aspergillus Spp PCR Test, PCR Test, CMV PCR Test, EBV PCR Test, BKV PCR Test, and VZV PCR Test. Implementing these strategic frameworks enables market participants to harmonize with their organizational activities, enhancing operational efficiency and aligning efforts with the dynamic landscape of transplant diagnostics.
Hence, these strategic initiatives by the market players may be expected to act as an opportunity for market growth.
Restraints/Challenges
- Shortage of Professionals with Expertise in Transplant Diagnostics
Shortage of skilled professionals may result in limited accessibility to specialized transplant diagnostic services. This could be particularly challenging for healthcare facilities in regions with a scarcity of trained personnel, leading to delayed or inadequate diagnostic support for organ transplant procedures. The shortage of experts in transplant diagnostics may compromise the quality and accuracy of diagnostic assessments. Lack of specialized knowledge and experience could result in errors in interpreting test results, potentially impacting the success rates of organ transplantation.
This may also impact research and development efforts in transplant diagnostics. Insufficient expertise may slow down the pace of innovation, hindering the development of new diagnostic technologies and approaches, which is restraining the market growth
- Ethical Challenges Faced During Organ Transplantation
The escalating incidence of vital organ failures, coupled with an insufficient supply, has created a pronounced gap between the growing demand for organs and their limited availability. This critical issue has not only prolonged approval times for organ recipients but has also contributed to a rise in fatalities. In addressing this pressing challenge, PCR-based diagnostic tests play a pivotal role, helping ensure the compatibility and viability of organs for transplantation. Tests such as the HLA Typing PCR Test and Cytomegalovirus (CMV) PCR Test are instrumental in determining the compatibility between donors and recipients, aiding in efficient organ allocation and reducing approval times.
It is therefore apparent that ethical challenges faced during organ transplantation are expected to challenge market growth.
Recent Developments
- In January 2024, Laboratory Corporation of America Holdings launched a new test for preeclampsia in pregnant women which represents a significant advancement in maternal healthcare. This advanced diagnostic tools, healthcare providers can identify women at higher risk of severe preeclampsia earlier in their pregnancies. This allows the company for more vigilant monitoring and proactive medical intervention, potentially reducing the risk of complications and improving maternal and fetal outcomes
- In September 2023, Sonic Healthcare's acquired Healius Ltd., to provide development in the Australian healthcare landscape. This acquisition further solidifies Sonic's position as a global leader in pathology, strengthening its competitive edge against other international players. It signifies the company's commitment to expansion and consolidation within the industry, potentially paving the way for similar mergers in other regions
- In October 2023, Sonic Healthcare's invested in PaigeAI, an AI-powered pathology company, underscores their commitment to harnessing cutting-edge technology for improved diagnostic accuracy and efficiency in the field of pathology. This move holds significant implications for the future of medical diagnostics. This precision approach can lead to more effective treatments and potentially reduce the risk of side effects from unnecessary medications
- In August 2020, Eurofins Viracor collaborated with the Northwestern University Comprehensive Transplant Center, a leader in solid organ transplantation medicine in North America, through high-impact research and its clinical training programs. This research collaboration has further verified the novel test obtained through Eurofins’ recent acquisition of Transplant Genomics Inc. (“TGI”) and its blood gene expression test, TruGraf. TruGraf can rule out “silent” subclinical kidney rejection in kidney transplant patients with stable kidney function. TGI has recently received a draft Local Coverage Determination (LCD) decision from the Centers for Medicare & Medicaid Services (CMS) via Palmetto GBA’s Molecular Diagnostic Services (MolDX) Program. This has helped the company to validate its research
- In June 2020, Transplant Genomics, Inc. and Eurofins Viracor announced the development of the Eurofins Transplant Medical and Scientific Advisory Board, engaging diverse expertise and understanding in transplantation and technology development to improve the clinical value of diagnostics throughout the transplant community. Board associates are focusing on improvement and product development, utilizing their unique perspectives to help TGI and Viracor expand to serve the unmet needs in transplantation and guide future products. This has helped the company to expand its product portfolio
Global PCR Based Transplant Diagnostics Market Scope
The global PCR based transplant diagnostics market is categorized into four notable segments based on test type, transplant type, application, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Test Type
- CMV PCR Test
- EBV PCR Test
- BKV PCR Test
- VZV PCR Test
- HSV1 PCR Test
- HSV2 PCR Test
- Parvovirus B19 PCR Test
- P. Jirovecii PCR Test
- JCV PCR Test
- Adenovirus PCR Test
- Aspergillus Spp PCR Test
On the basis of test type, the global PCR based transplant diagnostics market is segmented into CMV PCR test, EBV PCR test, BKV PCR test, VZV PCR test, HSV1 PCR test, HSV2 PCR test, Parvovirus B19 PCR test, P. Jirovecii PCR test, JCV PCR test, Adenovirus PCR test, and Aspergillus Spp PCR test.
Transplant Type
- Kidney Transplantation
- Liver Transplantation
- Heart Transplantation
- Lung Transplantation
- Pancreas Transplantation
- Other Transplantations
On the basis of transplant type, the global PCR based transplant diagnostics market is segmented into kidney transplantation, liver transplantation, heart transplantation, lung transplantation, pancreas transplantation, and other transplantations.
Application
- Diagnostic Applications
- Research Applications
On the basis of application, the global PCR based transplant diagnostics market is segmented into diagnostic application, and research applications.
End User
- Hospitals and Transplant Centers
- Commercial Service Providers
- Research Laboratories and Academic Institutes
On the basis of end user, the global PCR based transplant diagnostics market is segmented into hospitals and transplant centers, commercial service providers, and research laboratories and academic institutes.
Global PCR Based Transplant Diagnostics Market Regional Analysis/Insights
The global PCR based transplant diagnostics market is categorized into four notable segments based on test type, transplant type, application, and end user.
The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of Middle East and Africa.
North America is expected to dominate the market due to the presence of major market players and increased technological advancement in the region. The U.S. is expected to dominate the North America region due to rising demand for organ transplantation in the country. Germany is expected to dominate Europe region owing to the rising awareness about the application of PCR (Polymerase Chain Reaction) based transplant diagnostics in the country. China is expected to dominate Asia-Pacific region due to rising prevalence of kidney failure across the country.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Global PCR Based Transplant Diagnostics Market Share Analysis and Competitive Landscape
Global PCR based transplant diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, product type lifeline curve. The above data points provided are only related to the company’s focus on the global PCR based transplant diagnostics market.
Some of the major players operating in the market are Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Eurofins Viracor, LLC, Sonic Healthcare USA, Ambar Lab, ARUP Laboratories, and Dr. Lal PathLabs among others.
SKU-